MCE 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务。
Tucidinostat
CAS No. : 1616493-44-7
MCE 国际站:Tucidinostat
产品活性:Tucidinostat (Chidamide) 是一种有效的,可口服的 HDAC 第 I 类 HDAC1/2/3 和第 IIb 类 HDAC10 的抑制剂,IC50 值分别为 95,160,67 和 78 nM,对 HDAC8 和 HDAC11 的作用较弱 (IC50,733 nM,432 nM),对 HDAC4/5/6/7/9 无作用。
研究领域:Cell Cycle/DNA Damage | Epigenetics
作用靶点:HDAC
In Vitro: Tucidinostat (Chidamide/CS055/HBI-8000) is a potent and orally bioavailable HDAC enzymes class I (HDAC1, 2, 3) and class IIb (HDAC10) inhibitor, with IC50s of 95, 160, 67 and 78 nM, less active on HDAC8 and HDAC11 (IC50s, 733 nM, 432 nM, respectively), and shows no effect on HDAC4/5/6/7/9 (IC50s, >30 μM). Tucidinostat shows potent antitumor activity, and inhibits several human derived tumor cell lines, such as HL-60, U2OS, LNCaP with GI50s of 0.4 ± 0.1, 2.0 ± 0.6, and 4.0 ± 1.2 μM, respectively. In addition, Tucidinostat shows less toxic to normal cells from human fetal kidney (CCC-HEK) and liver (CCCHEL).
In Vivo: Tucidinostat (12.5-50 mg/kg, p.o.) dose-dependently reduces tumor size and tumor weight in mice bearing HCT-8 colorectal carcinoma, A549 lung carcinoma, BEL-7402 liver carcinoma, and MCF-7 breast carcinoma, and with no obvious body loss.
相关产品:Covalent Screening Library Plus | Drug Repurposing Compound Library Plus | FDA-Approved Drug Library Plus | FDA-Approved Drug Library Mini | Bioactive Compound Library Plus | Cell Cycle/DNA Damage Compound Library | Epigenetics Compound Library | FDA-Approved Drug Library | Histone Modification Research Compound Library | Anti-Cancer Compound Library | Antiviral Compound Library | Anti-Aging Compound Library | Drug Repurposing Compound Library | Covalent Screening Library | Reprogramming Compound Library | Oxygen Sensing Compound Library | Anti-COVID-19 Compound Library | NMPA-Approved Drug Library | Orally Active Compound Library | FDA Approved & Pharmacopeial Drug Library | Anti-Breast Cancer Compound Library | Anti-Pancreatic Cancer Compound Library | Anti-Blood Cancer Compound Library | Targeted Therapy Drug Library | Anti-Liver Cancer Compound Library | FDA-Approved Anticancer Drug Library | Human Metabolite Library | Anti-Pulmonary Fibrosis Compound Library | Osteogenesis Compound Library | Heterocyclic Compound Library | Cysteine Targeted Covalent Library | Anti-Hematopathy Compound Library | Multi-Target Compound Library | Bioactive Compound Library Max | Trichostatin A | 4-Phenylbutyric acid | Vorinostat | Valproic acid | Sulforaphane | Panobinostat | Entinostat | Romidepsin | RGFP966 | Belinostat | Tubastatin A | Ricolinostat | Carbamazepine | Mocetinostat | TMP195 | Theophylline | Tasquinimod | ITSA-1 | LMK-235 | Quisinostat | Santacruzamate A | Tubacin | TMP269 | Fimepinostat | PCI-34051 | FT895 | Pyroxamide
热门产品线:重组蛋白 | 药物筛选 | 天然产物 | 荧光染料 | PROTAC | 同位素标记物
Trending products:Recombinant Proteins | Bioactive Screening Libraries | Natural Products | Dye Reagents | PROTAC | Isotope-Labeled Compounds
品牌介绍:
• MCE (MedChemExpress) 拥有200 多种全球独家化合物库,我们致力于为全球科研客户提供前沿最全的高品质小分子活性化合物;
• 50,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域;
• 产品种类涵盖各种重组蛋白,多肽,常用试剂盒 ,更有 PROTAC、ADC 等特色产品,广泛应用于新药研发、生命科学等科研项目;
• 提供虚拟筛选,离子通道筛选,代谢组学分析检测分析,药物筛选等专业技术服务;
• 设有专业的实验中心和严格的质控、验证体系;
• 提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告,确保产品的高纯度、高品质;
• 产品的生物活性多经各国客户实验验证;
• Nature, Cell, Science 等多种顶级期刊及制药专利收录了MCE客户的科研成果;
• 专业团队跟踪最新的制药及生命科学研究进展,为您提供全球最新的活性化合物;
• 与世界各大制药公司及知名科研机构建立了长期的合作。